Skip to main content

Diabetes and Numbers


Hispanic, 43 year old female
Lots of stress in life
Diabetes for 2 years
Currently on Metformin 1000 mg BY MOUTH twice daily.

Clinic ran comprehensive metabolic panel.
Blood glucose 216, Hemoglobin A1C is 7.8

(ADA guideline: A1C of 6.5 or greater, confirmed diabetes with repeat)
High triglycerides and cholesterol.

Diabetes and numbers:

 American College of Physicians (ACP), in 2018 proposed changing the recommended A1C target guidelines.Based on outcomes and taking side effects and cost in to consideration they recommend patients with type 2 diabetes should aim to achieve an HbA1C between 7 and 8 percent instead of 6.5 to 7 percent, as previously advised by ADA. 

 The American Diabetes Association did not like the suggestions stating the old standard are better, saying that a “reasonable A1C goal for many non pregnant adults with Type 2 diabetes is less than 7 percent.

 We went with ADA guidelines and added Glyburide 5 mg daily with largest meal of the day Fenofibrate 145 mg daily with increase in activity/exercise and controlled diet.










Comments

  1. MaudMedicalApril 1, 2022 at 2:32 AM

    You have worked nicely with your insights that makes our work incontinence calgary. The information you have provided is really factual and significant for us. Keep sharing these types of article, Thank you.

    ReplyDelete
  2. ACA AdvisorJanuary 5, 2023 at 9:25 PM

    clearly, It is an engaging article for us which you have provided here about Best health insurance in Miami This is a great resource to enhance knowledge about it. Thank you.

    ReplyDelete

Post a Comment

Popular posts from this blog

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...
Post a Comment
Read more

Thyroid health- Quality of Life

  Let's get a TSH blood test for our family and friends Normal serum TSH ranges are higher in the  people age 70 to 80 years ; based on this, higher serum TSH goals may be needed as a patient ages.  The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 m IU/L for 70 years-old and up The thyroid is a small, butterfly-shaped hormone-producing gland located at the front of the neck. The thyroid gland secretes two main hormones:  thyroxine (T-4) and triiodothyronine (T-3).   These hormones regulate energy levels, metabolism of fats, proteins and carbohydrates, body temperature, heart rate.  Hypothyroidism happens when the underactive thyroid gland doesn't make enough hormones. Hypothyroidism affects up to 10% of the general population (5% undiagnosed) . A n autoimmune disease called Hashimoto's diseas e where our body  makes antibodies that attack healthy thyroid tissues  is the most common cause of hypothyroidism in soc...
Post a Comment
Read more

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...
7 comments
Read more